Plain-English translation of NCT06602037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing new imaging scans that use special tracers—called immunoPET scans—to help doctors find and measure pancreatic cancer. The tracers work by targeting specific proteins that pancreatic cancer cells often have on their surface. Researchers want to see if these scans can accurately detect cancer and help guide treatment decisions.
Current imaging methods sometimes miss pancreatic cancer or can't tell the difference between cancerous and non-cancerous tissue. This medication aims to make imaging more precise so doctors can catch cancer earlier and plan better treatment.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of a special imaging tracer and then undergo whole-body imaging scans (PET/CT) at various time points—either over several days or about an hour after the injection, depending on which tracer is used. The scans will show how much of the tracer accumulates in your cancer and normal tissues, helping doctors measure how well the treatment is working. The study involves no ongoing medication—just the imaging visits.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Sponsor
RenJi Hospital
Enrollment target
~90 participants
Started
November 2024
Primary completion
June 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weijun Wei, Ph.D. & M.D.
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.